Comparison of ofatumumab and other disease-modifying therapies for relapsing multiple sclerosis: a network meta-analysis.

Conclusion: Ofatumumab offers beneficial outcomes for RMS by reducing relapse and disability progression risk. PMID: 33090003 [PubMed - as supplied by publisher]
Source: Journal of Comparative Effectiveness Research - Category: General Medicine Tags: J Comp Eff Res Source Type: research